Cellular health screening test is a laboratory tests that analyze a patient’s blood or saliva sample to detect microscopic changes in cells indicative of early-stage diseases, risk factors and biomarkers that can predict future health issues. This helps in early detection and prevention of various chronic and life-threatening diseases. Common cellular health screening tests includes genomic testing, epigenetic testing, telomere testing, microbiome testing and proteomic testing. Genomic testing analyze single nucleotide polymorphisms (SNPs) to determine genetic risks for diseases like cancer, heart disease and diabetes.
The global cellular health screening test market is estimated to be valued at US$ 1.2 billion in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
According to World Health Organization (WHO), chronic diseases such as cancer, diabetes and heart disease are the leading causes of death and disability globally. It accounted for approximately 63% of all deaths in 2020. According to Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the United States live with at least one chronic disease, like heart disease, cancer or diabetes. Chronic diseases are long-lasting and generally slow-progressing diseases. Early detection of such diseases enable timely prevention and management measures to reduce disease burden. This is increasing the demand for various cellular health screening tests that can identify cellular biomarkers indicating risks of chronic diseases at an early stage.
Another key driver of the market is advancements in genomics, epigenomics, proteomics and microbiome sequencing technologies that are enabling development of novel cellular health screening tests. Revolution in molecular biology techniques like next-generation sequencing, machine learning and artificial intelligence facilitated deeper understanding of interactions between genes, environment and lifestyle that cause or prevent diseases. This is fueling development of advanced multi-omics based cellular health screening tests with higher accuracy and ability to detect multiple health conditions simultaneously.
Segment Analysis
The global cellular health screening test market is segmented into general health and disease testing. Among these, the general health and wellness testing segment dominates the market and accounts for over 60% share. This is because of growing preference among individuals to maintain good health and prevent diseases. Regular checkup for parameters like blood glucose, cholesterol etc help in early detection of risk and taking corrective actions.
PEST Analysis
Political: Governments in many countries are promoting preventive healthcare through awareness programs. Favorable regulations have allowed private players to offer cellular screening tests.
Economic: Rising income levels have increased discretionary spending on health. People are willing to spend on regular tests to avoid high medical bills in future. Various health insurance plans cover costs of annual checkups.
Social: Better education about link between lifestyle and diseases. People actively track health metrics and maintain healthy habits. Social media has raised health consciousness.
Technological: Advanced technologies like microfluidics based biochips have made testing simple, fast and affordable. Automated processes have improved accuracy and reliability of results. Digital health platforms help monitor trends over time.
Key Takeaways
The Global Cellular Health Screening Test Market Size is expected to reach USD 12 Billion by 2031 from USD 7 Billion in 2024, witnessing a CAGR of 6.7% during the forecast period.
North America region dominates currently due to higher diagnostic spending and more number of testing facilities.
Key players operating in the cellular health screening test market are Thermo Fisher Scientific Inc., Quest Diagnostics, LifeLabs, Ravgen, Telo Years, Sema4, Genetic Testing Services, Inc. and others. The market is competitive with players focusing on product innovation, geographical expansion and tie-ups with diagnostic chains & hospitals. Digital solutions are being integrated which help customers better engage with their cellular health data over time. Growth opportunities lie in increasing awareness about benefits of regular screening through social media campaigns and insurance coverage for preventive health checks.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it